The German biotechnology company BioNTech announced that it plans to produce up to 2.5 billion doses of the vaccine, which it developed in cooperation with the American Pfizer in 2021, ie a quantity 25% higher than previously announced, according to APE.
Production capacity should be increased due to production optimization, expansion of the production network, as well as the export license for six doses per vial, the company explains in a statement.
Until March 23, the BionTech and Pfizer had delivered more than 200 million doses of their vaccine worldwide.
Last week, European regulatory authorization of the new Marburg plant, which is added to the Belgian plant in Pours, is expected to boost BioNTech’s production capacity by producing 250 million doses in the first half of the year, to reach the long-term one billion doses per year.
The vaccine, the first to be marketed in the United States and the European Union, is now available in more than 65 countries and regions, according to Ugur Sahin, co-founder with his wife of the German biotechnology company.
“We are already seeing the first signs of a drop in Covid-19 cases and mortality in many countries,” explained Ugur Sahin, adding that the biotechnology lab is now focusing on virus variants and conducting additional clinical trials. A vaccine study has also been started in children aged 6 months to 12 years.
In total, BioNTech has orders for 1.4 billion installments this year and forecasts an increase in demand, according to the announcement.
The German-American partnership also has three production units in the United States.
Recently, the European Medicines Agency (EMA) authorized the storage of the vaccine in freezing conditions, higher than the deep-freezing temperatures that existed until then, facilitating the operation of the supply chain.
The vaccine against Covid-19 brought BioNTech an annual profit of 15.2 million euros last year, compared to a loss of 179.2 million euros in 2019, according to the financial results released today.
The company expects total revenue of 9.8 billion euros under the contracts signed, along with an increase in investment in research and development in 2021.
In total, BioNTech spent € 645 million on research in 2020, a vertical increase due to the development of the Covid-19 vaccine.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
